B. Riley raised the firm’s price target on Perspective Therapeutics to $1.70 from $1.20 and keeps a Buy rating on the shares. The firm has increased confidence of a Phase III initiation of Perspective’s alpha-NET in 1L NET in 2025 and potential market entry in 1Q30, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics to Participate at Upcoming April Investor Conferences
- Perspective Therapeutics price target raised to $1.50 from $1.20 at Oppenheimer
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
- Perspective Therapeutics sees cash runway into 2026
- Perspective Therapeutics reports 2023 EPS (17c) vs. (8c) last year
